Video

Mark Cuban Cost Plus Drug Company confers savings on urologic drugs

Author(s):

Urology Times staff

“I would say that we did not anticipate the degree of potential cost savings,” says Ruchika Talwar, MD.

In this video, Ruchika Talwar, MD, discusses the background and notable findings from the Journal of Urology paper, “Urologic Drug Price Stewardship – Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model.” Talwar is a urologic oncology fellow at Vanderbilt University Medical Center in Nashville, Tennessee.

Related Videos
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Related Content
Urologists perform first remote robot-assisted HIFU for prostate cancer
April 17th 2025

Urologists perform first remote robot-assisted HIFU for prostate cancer

Hannah Clarke
“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study underway to assess 3-fraction SBRT regimen in prostate cancer
April 14th 2025

Study underway to assess 3-fraction SBRT regimen in prostate cancer

Hannah Clarke
"The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Genetic test can predict risk of toxicity following radiation for prostate cancer
April 7th 2025

Genetic test can predict risk of toxicity following radiation for prostate cancer

Hannah Clarke
"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
What urologists can expect in Q2 of 2025
April 7th 2025

What urologists can expect in Q2 of 2025

Hannah Clarke Benjamin P. Saylor
A lookahead of the notable FDA decisions and conferences slated for Q2 2025.
© 2025 MJH Life Sciences

All rights reserved.